Welcome to our dedicated page for Anebulo Pharmaceuticals SEC filings (Ticker: ANEB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anebulo Pharmaceuticals' SEC filings provide detailed disclosure of the company's clinical development activities, financial position, and regulatory status as a clinical-stage biopharmaceutical entity. For investors analyzing small-cap biotech companies, these documents reveal critical information about research progress, cash runway, and business risks inherent in drug development.
The company's Form 8-K filings document material events including clinical trial announcements, regulatory interactions, and significant corporate decisions such as exchange listing changes. These current reports often contain the most time-sensitive information for tracking development milestones. Quarterly reports (10-Q) and annual reports (10-K) detail research and development expenditures, clinical trial progress, regulatory pathway discussions, and going concern assessments that reveal the company's financial sustainability.
For clinical-stage pharmaceutical companies, SEC filings serve as the primary source for understanding pipeline status, trial enrollment progress, and the substantial capital requirements of drug development. Anebulo's disclosures include details about grant funding from government agencies, collaboration agreements, and the regulatory approval pathways the company pursues for its cannabinoid intoxication and substance use disorder treatments.
Investors can also track Form 4 insider transactions to monitor stock purchases and sales by company executives and directors, potentially signaling management's confidence in development prospects. Proxy statements (DEF 14A) reveal executive compensation structures and governance matters relevant to evaluating how the company aligns management incentives with shareholder interests during the high-risk clinical development process.
Anebulo Pharmaceuticals plans to start a cash tender offer on December 22, 2025 to buy up to 300,000 shares of its common stock at $3.50 per share, for a maximum of $1,050,000. This voluntary self-tender is part of a strategy to complete a “go private” transaction by keeping the number of stockholders below 300.
The board has decided to abandon a previously proposed reverse stock split, which would have paid $3.50 per fractional share, after activity by some holders using multiple small accounts significantly increased the expected cost. Instead, the company will proceed with the tender offer, while reserving the right to consider a reverse split or other alternatives in the future. The tender offer has not yet commenced and will proceed only under the terms described in formal offer documents that will be sent to stockholders and filed with the SEC.
Anebulo Pharmaceuticals (ANEB) reported Q1 FY2026 results with a net loss of $2,158,354 as it advances selonabant for cannabis-induced toxicity. Operating expenses were $2,260,260, with research and development at $809,991 (lower due to timing of studies) and general and administrative at $1,450,269 (higher from professional fees related to a potential going‑private transaction). Other income, net, was $101,906, aided by interest income.
Cash and cash equivalents were $10,354,773 as of September 30, 2025, and management believes this, along with availability under a $3,000,000 Loan Agreement accruing at 0.25% per annum, will fund operations for at least 12 months. No amounts were drawn under the facility. Net cash used in operating activities was $1,273,076 for the quarter.
The company received a notice of award on September 2, 2025 for Year 2 of its NIDA grant (approximately $1.0 million) to support IV selonabant development. Shares outstanding were 41,084,731 as of September 30, 2025. A Special Committee continues to evaluate strategic alternatives, including a proposed reverse stock split within a 1‑for‑2,500 to 1‑for‑7,500 range as part of a potential going‑private process.
Anebulo Pharmaceuticals (ANEB) is seeking shareholder approval for a reverse stock split at a board-determined ratio between 1-for-2,500 and 1-for-7,500, with the Board able to set the final ratio within that range or abandon the amendment. Fractional post-split shares will be cashed out at
The proxy explains the Board and a Special Committee considered market liquidity, valuation approaches (market and income methods), a fairness opinion from Houlihan Capital, and recent affiliate purchases (private placement at
Anebulo Pharmaceuticals (ANEB) filed its Form 10-K reporting 41,084,731 shares outstanding and a market value of approximately $15,057,677 based on the Nasdaq close on December 31, 2024. The company recorded an accumulated deficit of $73.9 million as of June 30, 2025 and expects to continue generating operating losses. Management states cash, cash equivalents and available funding under its Loan Agreement should fund operations for at least 12 months from issuance of the financial statements. During the year the company completed a private placement of 15,151,514 shares for gross proceeds of about $15.0 million and issued warrants exercisable at $4.215 until September 28, 2027. Grant income of $0.9 million was recognized and a Loan Agreement providing up to $10 million remains available with no balance outstanding at June 30, 2025.
Anebulo Pharmaceuticals seeks stockholder approval for a reverse stock split at a ratio set within a 1-for-2,500 to 1-for-7,500 range, with the Board able to pick the exact ratio or abandon the amendment. Fractional post-split shares will be cashed out at $3.50 per share. At a midpoint 1-for-5,000 ratio, the company estimates approximately $4.1 million will be required to retire fractional shares; low and high estimates are $3.2 million and $4.7 million, respectively, plus estimated Transaction fees of about $1.0 million. The company expects to pay these amounts from cash on hand, which on March 31, 2025 included $13.3 million of cash and equivalents and $3.0 million of debt. The Special Committee obtained a fairness opinion from Houlihan Capital and noted that the $3.50 Cash Payment represents a premium to recent prices (111% to the July 11, 2025 close of $1.66; 116% to 30‑day VWAP of $1.62; 150% to 90‑day VWAP of $1.40). The proxy discloses concentrated ownership (e.g., 22NW ~40.1% and a director Aron R. English ~51.2% beneficially) and pro forma outstanding shares post-split (pro forma example: 7,980 shares after a 1-for-5,000 split).
FAQ
What is the current stock price of Anebulo Pharmaceuticals (ANEB)?
What is the market cap of Anebulo Pharmaceuticals (ANEB)?
